Skip to main content Skip to main navigation menu Skip to site footer
  • \
    Start Submission Become a Reviewer

    Blood biomarkers in MCI conversion to Alzheimer’s disease: a systematic review and meta-analysis

    • Hai-Xia Li
    • Jin-Tao Wang
    • Yu Dong
    • Jian-Ping Li
    • Jin-Wen Xiao
    • Ru-Jing Ren
    • Chun-Bo Li
    • Gang Wang


    Abstract

    Background: The predictive effects of blood biomarkers (BBMs) in the progression of Alzheimer’s disease (AD) have been reported recently. However, controversies still exist. In the present study, we aim to identify the predictive performances of BBMs in the conversion from Mild cognitive impairment (MCI) to AD.

    Methods: PubMed, Embase, Cochrane Library, and Web of Science from inception to June 10, 2023 were searched. Predictive potentials were evaluated by pooling the ratio of means (ROMs), relative risks (RRs), and diagnostic indexes from MCI-converters (MCI-c: MCI patients who convert to AD) and MCI-non converters (MCI-nc) based on fixed-effects or random-effects. Newcastle–Ottawa Quality Assessment Scale (NOS) was applied for quality assessment.

    Results: A total of 44 studies with 9343 participants from 28 cohorts were included in the meta-analysis, whereas the other 45 articles were included in the qualitative review. The average score of 44 studies included in the meta-analysis was 7.125. In pooled ROMs, plasma Aβ42/Aβ40 was lower, whereas Aβ40, T-tau, P-tau 181, P-tau 217, NFL, and GFAP were higher in MCI-c than MCI-nc. In pooled RRs, P-tau (RR=2.50, 95%CI: 2.04-3.06) as a continuous variable, Aβ42/Aβ40 as a categorical variable (RR=1.28, 95%CI: 1.01-1.61) could predict future conversion risk of MCI patients. In diagnostic indexes, the diagnostic odds ratio (DOR) was 42 for P-tau 217 (sensitivity: 91%; specificity: 81%), 15 for P-tau 181 (sensitivity: 81%; specificity: 78%), 12.71 for GFAP (sensitivity: 71%; specificity: 86%), 6 for Aβ42/Aβ40 (sensitivity: 86%; specificity: 49%, and 6 for NFL (sensitivity: 80%; specificity: 61%).

    Conclusion: Here, our results indicated that blood biomarkers held promising potential in predicting MCI conversion. However, more prospective cohorts based on particular MCI types and high-sensitivity assays are warranted to validate the results next.

    Keywords: blood biomarkers mild cognitive impairment Alzheimer’s disease
    Section

    References

    1. Alzheimer's disease facts and figures. [J]. Alzheimers Dement,2023, 19(4): 1598-1695.
    2. Albert, M. S., DeKosky, S. T., Dickson, D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].Alzheimers Dement,2011, 7(3): 270-279.
    3. Ashton, N. J., Janelidze, S., Mattsson-Carlgren, N., et al. Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring [J].Nat Med,2022, 28(12): 2555-2562.
    4. Barthélemy, N. R., Horie, K., Sato, C., et al. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease [J].J Exp Med,2020, 217(11).
    5. Benedet, A. L., Milà-Alomà, M., Vrillon, A., et al. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum [J].JAMA Neurol,2021, 78(12): 1471-1483.
    6. Bilgel, M., An, Y., Walker, K. A., et al. Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid [J].Alzheimers Dement,2023.
    7. Fei, M., Jianghua, W., Rujuan, M., et al. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment [J].J Neurol Sci,2011, 305(1-2): 92-96.
    8. Friedrich, J. O., Adhikari, N. K., & Beyene, J. The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study [J].BMC Med Res Methodol,2008, 8: 32.
    9. Hampel, H., Cummings, J., Blennow, K., et al. Developing the ATX(N) classification for use across the Alzheimer disease continuum [J].Nat Rev Neurol,2021, 17(9): 580-589.
    10. Hansson, O., Edelmayer, R. M., Boxer, A. L., et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease [J].Alzheimers Dement,2022, 18(12): 2669-2686.
    11. Huang, S., Wang, Y. J., & Guo, J. Biofluid Biomarkers of Alzheimer's Disease: Progress, Problems, and Perspectives [J].Neurosci Bull,2022, 38(6): 677-691.
    12. Jack, C. R., Jr., Bennett, D. A., Blennow, K., et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease [J].Alzheimers Dement,2018, 14(4): 535-562.
    13. Janelidze, S., Bali, D., Ashton, N. J., et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease [J].Brain,2023, 146(4): 1592-1601.
    14. Janelidze, S., Barthélemy, N. R., He, Y., et al. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios [J].JAMA Neurol,2023, 80(5): 516-522.
    15. Janelidze, S., Mattsson, N., Palmqvist, S., et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia [J].Nat Med,2020, 26(3): 379-386.
    16. Karikari, T. K., Ashton, N. J., Brinkmalm, G., et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility [J].Nat Rev Neurol,2022, 18(7): 400-418.
    17. Koini, M., Pirpamer, L., Hofer, E., et al. Factors influencing serum neurofilament light chain levels in normal aging [J].Aging (Albany NY),2021, 13(24): 25729-25738.
    18. Li, R. X., Ma, Y. H., Tan, L., et al. Prospective biomarkers of Alzheimer's disease: A systematic review and meta-analysis [J].Ageing Res Rev,2022, 81: 101699.
    19. McInnes, M. D. F., Moher, D., Thombs, B. D., et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement [J].Jama,2018, 319(4): 388-396.
    20. McKhann, G., Drachman, D., Folstein, M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease [J].Neurology,1984, 34(7): 939-944.
    21. McKhann, G. M., Knopman, D. S., Chertkow, H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].Alzheimers Dement,2011, 7(3): 263-269.
    22. Mielke, M. M., Dage, J. L., Frank, R. D., et al. Performance of plasma phosphorylated tau 181 and 217 in the community [J].Nat Med,2022, 28(7): 1398-1405.
    23. Milà-Alomà, M., Ashton, N. J., Shekari, M., et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease [J].Nat Med,2022, 28(9): 1797-1801.
    24. Moscoso, A., Grothe, M. J., Ashton, N. J., et al. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum [J].Brain,2021, 144(1): 325-339.
    25. Oeckl, P., Anderl-Straub, S., Von Arnim, C. A. F., et al. Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion [J].J Neurol Neurosurg Psychiatry,2022.
    26. Olsson, B., Lautner, R., Andreasson, U., et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis [J].Lancet Neurol,2016, 15(7): 673-684.
    27. Palmqvist, S., Janelidze, S., Stomrud, E., et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status [J].JAMA Neurol,2019, 76(9): 1060-1069.
    28. Palmqvist, S., Stomrud, E., Cullen, N., et al. An accurate fully automated panel of plasma biomarkers for Alzheimer's disease [J].Alzheimers Dement,2022.
    29. Petersen, R. C. Mild cognitive impairment as a diagnostic entity [J].J Intern Med,2004, 256(3): 183-194.
    30. Qu, Y., Ma, Y. H., Huang, Y. Y., et al. Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis [J].Neurosci Biobehav Rev,2021, 128: 479-486.
    31. Simrén, J., Andreasson, U., Gobom, J., et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years [J].Brain Commun,2022, 4(4): fcac174.
    32. Simrén, J., Weninger, H., Brum, W. S., et al. Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability [J].Alzheimers Dement,2022, 18(10): 1988-1992.
    33. Smirnov, D. S., Ashton, N. J., Blennow, K., et al. Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change [J].Acta Neuropathol,2022, 143(4): 487-503.
    34. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses [J].Eur J Epidemiol,2010, 25(9): 603-605.
    35. Stocker, H., Beyer, L., Perna, L., et al. Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years [J].Alzheimers Dement,2023, 19(1): 25-35.
    36. Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation [J].Lancet Neurol,2022, 21(1): 66-77.
    37. Thijssen, E. H., La Joie, R., Strom, A., et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study [J].Lancet Neurol,2021, 20(9): 739-752.
    38. Wang, J. T., Xu, G., Ren, R. J., et al. The impacts of health insurance and resource on the burden of Alzheimer's disease and related dementias in the world population [J].Alzheimers Dement,2022.
    39. Wang, Z. B., Tan, L., Wang, H. F., et al. Differences between ante mortem Alzheimer's disease biomarkers in predicting neuropathology at autopsy [J].Alzheimers Dement,2023.
    40. Xiao, Z., Wu, W., Ma, X., et al. Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment [J].Clin Chem,2022, 68(12): 1552-1563.
    41. Yakoub, Y., Ashton, N. J., Strikwerda-Brown, C., et al. Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease [J].Alzheimers Dement,2023.

    How to Cite

    “Blood Biomarkers in MCI Conversion to Alzheimer’s Disease: A Systematic Review and Meta-Analysis”. Human Brain, vol. 2, no. 2, Nov. 2023, https://doi.org/10.37819/hb.2.1758.
    ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
    Download Citation
    Endnote/Zotero/Mendeley (RIS) BibTeX

    How to Cite

    “Blood Biomarkers in MCI Conversion to Alzheimer’s Disease: A Systematic Review and Meta-Analysis”. Human Brain, vol. 2, no. 2, Nov. 2023, https://doi.org/10.37819/hb.2.1758.

    HTML
    302

    Total
    85 48

    Share

    Search Panel

    Hai-Xia Li
    Google Scholar
    Pubmed
    JDMFS Journal

    Jin-Tao Wang
    Google Scholar
    Pubmed
    JDMFS Journal

    Yu Dong
    Google Scholar
    Pubmed
    JDMFS Journal

    Jian-Ping Li
    Google Scholar
    Pubmed
    JDMFS Journal

    Jin-Wen Xiao
    Google Scholar
    Pubmed
    JDMFS Journal

    Ru-Jing Ren
    Google Scholar
    Pubmed
    JDMFS Journal

    Chun-Bo Li
    Google Scholar
    Pubmed
    JDMFS Journal

    Gang Wang
    Google Scholar
    Pubmed
    JDMFS Journal

    Downloads

    Article Details

    Most Read This Month

    License

    Copyright (c) 2023 Hai-Xia Li, Jin-Tao Wang, Yu Dong, Jian-Ping Li, Jin-Wen Xiao, Ru-Jing Ren, Chun-Bo Li , Gang Wang

    Creative Commons License

    This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

    Most read articles by the same author(s)

    Copyright © 2023 EurAsia Academic Publishing Group. All rights reserved